AKSHAYA VISWANATHAN,PRABAKARAN B,NEHA BRAHMA,VIMAL S,DR.GOLD PEARLIN MARY
DOI: https://doi.org/Breast cancer diagnosis is advancing through liquid biopsy, a minimally invasive method analyzingtumor-derived biomarkers in blood. Circulating tumor DNA (ctDNA), CTCs, EVs, and ncRNAs offer real-time insights into tumor dynamics, resistance, and subtypes. ctDNA enables early detection of recurrence, while ncRNA signatures guide prognosis and therapy. Integration with genomic strategies, such as using PARP inhibitors in BRCA1/2-deficient tumors, enhances treatment precision. This approach exploits synthetic lethality, selectively killing cancer cells while sparing normal ones. Emerging AI-driven multi-omics platforms promise personalized monitoring. Together, these innovations are reshaping breast cancer care.
